Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies

  • Technology appraisal guidance
  • TA772
  • Published: 

Evidence

Documents containing the evidence that was used to develop the recommendations.

Supporting evidence